/kg. No impacts of age, blood counts, or previous treatment with lenalidomide, bortezomib, or carfilzomib were observed. Our results suggest that LD-Cy may be considered for successful SC mobilization in patients with MM.
No takes yet. Share an insight, caveat, or question.
Zannetti et al. (2021) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: